Symmetry Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Symmetry Partners’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,683	Closed	-$493K	–	685
2021 Q2	$493K	Hold	2,683	–	–	0.03%	433
2021 Q1	$410K	Sell	2,683 -39	-1%	-$6.03K	0.03%	472
2020 Q4	$425K	Buy	2,722 +21	+0.8%	+$2.7K	0.03%	423
2020 Q3	$309K	Buy	+2,701	New	+$291K	0.03%	480

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Symmetry Partners's ALXN Position: Q3 2021 in Review

Symmetry Partners sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 2,683 shares — an estimated $493K sold.

Symmetry Partners first reported a position in ALXN in Q3 2020 and held it in 4 quarters. The position peaked at $493K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Symmetry Partners reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Symmetry Partners sold 2,683 Alexion Pharmaceuticals shares in Q3 2021, an estimated $493K.
Symmetry Partners first reported a position in Alexion Pharmaceuticals in Q3 2020 and held it in 4 quarters.
Symmetry Partners's Alexion Pharmaceuticals position peaked at $493K in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Symmetry Partners's 13F filing for Q3 2021, filed 18 Oct 2021.